In silico drug repurposing targeting fusion and nucleoprotein of human metapneumovirus: A step toward pandemic preparedness
The study highlights mobocertinib, rutin, and levetiracetam as promising repurposed drugs against HMPV. While mobocertinib exhibited the strongest predicted binding affinity, levetiracetam demonstrated the best pharmacokinetic profile, making it a particularly viable candidate for further experimental validation. These results validate the usefulness of in silico drug repurposing in addressing unmet antiviral needs and warrant preclinical studies to evaluate therapeutic efficacy.
Authors
- Hadiya Siddiqui (ORCID: https://orcid.org/0000-0002-7556-0825)
- Gajendra Choudhary (ORCID: https://orcid.org/0000-0002-4311-7466)
- Harshita Rajput
- Manisha Prajapat (ORCID: https://orcid.org/0000-0003-4239-7408)
- Ajay Prakash (ORCID: https://orcid.org/0000-0002-3487-8482)
- Anushka Ghosh (ORCID: https://orcid.org/0009-0001-3344-7592)
- Bikash Medhi
Institutions
- Chandigarh University (IN)
- University of the Punjab (PK)
- Post Graduate Institute of Medical Education and Research (IN)
- Stanford University (US)
Publication Details
- Journal
- Indian Journal of Pharmacology
- Published
- 2025-08-22
- DOI
- https://doi.org/10.4103/ijp.ijp_559_25
- Citations
- 1
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 1.35